Idiopathic Pulmonary Fibrosis
Industries, occupations with high IPF mortality in 2020 to 2022 differ by sex
Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical occupations, according to study findings.
Admilparant slows lung function decline in IPF, progressive PF
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC decline in idiopathic and progressive pulmonary fibrosis, according to study results.
Phase 1 trial of potential treatment for IPF moves forward ‘without any safety concerns’
No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has potential in treating idiopathic pulmonary fibrosis, in healthy individuals, according to a press release.
Deupirfenidone reduces FVC decline, well tolerated in IPF at 26 weeks
Patients with idiopathic pulmonary fibrosis had less FVC decline between baseline and 26 weeks with receipt of three daily doses of 825 mg deupirfenidone, according to phase 2b ELEVATE IPF trial results.
Neighborhood-level disadvantage negatively impacts lung function in IPF
Lung function of patients with idiopathic pulmonary fibrosis in California was poorer if they resided in disadvantaged vs. advantaged neighborhoods, according to results published in Annals of the American Thoracic Society.
Frailty negatively impacts lung function, survival in patients with IPF
Significant predictors of FVC and diffusion capacity of lung for carbon monoxide included frailty, low fat-free mass index and sarcopenia in patients with idiopathic pulmonary fibrosis, according to data published in Respiratory Research.
Poorer IPF quality of life reports in community pulmonary practices vs. ILD centers
BOSTON — Based on patient responses, quality of life with idiopathic pulmonary fibrosis was worse among those treated in community pulmonary practices vs. interstitial lung disease centers, according to data at the CHEST Annual Meeting.
Topline results: AI-established IPF drug well-tolerated, improves FVC
Patients with idiopathic pulmonary fibrosis had improved FVC between baseline and 12 weeks with receipt of ISM001-055, a small molecule targeting Traf2- and Nck-interacting kinase, vs. placebo, according to topline results.
Around 50% of patients with IPF report negative influence of symptoms on relationships
BOSTON — When presented with the statement, “I have trouble keeping up with my family, friends, children and/or grandchildren because of IPF” via online survey, 49% agreed, according to a poster presented at the CHEST Annual Meeting.
PAH, right ventricular hypertrophy prevalent in patients with ILD
BOSTON — Among patients with interstitial lung disease, 30% had pulmonary arterial hypertension and 20% had right ventricular hypertrophy, according to data presented at the CHEST Annual Meeting.